iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
Retrieved on:
Wednesday, March 27, 2024
BRYAN, Texas and SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) announces today that it has entered into a collaboration agreement with AstralBio, Inc. (“AstralBio”) to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions.
Key Points:
- Yesterday, iBio announced the closing of a $15 million private placement financing with ADAR1 Capital Management, Lynx1 Capital Management, Ikarian Capital and other institutional investors.
- The company will use a portion of the net proceeds to support new partnerships, such as this collaboration with AstralBio.
- The goal of this transformative collaboration is to rapidly build a novel, best-in-class cardiometabolic disease portfolio by combining iBio’s ability to create antibodies against hard-to-drug targets with AstralBio’s significant biologics experience and drug development expertise.
- iBio has the exclusive option to license three (3) cardiometabolic targets from AstralBio and will receive the rights to develop, manufacture and commercialize those targets upon exercise.